Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable

References

• Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063–72
   PubMed Web of Science ®Google Scholar
• Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8: 55–66
   PubMed Web of Science ®Google Scholar
• Kane J. Progress defined – Short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 2001; 16(Suppl 1)S1–8
   PubMedGoogle Scholar
• Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: A critical overview. Can Med Ass J 2005; 172: 1703–11
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 2002; 346: 16–22
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16: 473–84
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209–22
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability–Are patients better off?. Can J Psychiatry 2004; 49: 297–302
   PubMed Web of Science ®Google Scholar
• Lambert M, Naber D. Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18, (Suppl 2):5–17; discussion 41–3.
   PubMed Web of Science ®Google Scholar
• Marder SR. Overview of partial compliance. J Clin Psychiatry 2003; 64(Suppl 16)3–9
   PubMed Web of Science ®Google Scholar
• Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents?. Am J Psychiatry 2002; 159: 103–8
   PubMed Web of Science ®Google Scholar
• Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psychiatry 2003; 64: 1308–15
   PubMed Web of Science ®Google Scholar
• Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004; 14: 87–92
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692–9
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Engelhart LM, Janagap C, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder – Symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004; 24: 275–286
   PubMed Web of Science ®Google Scholar
• Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10: 464–79
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003; 64(Suppl 16)18–23
   PubMed Web of Science ®Google Scholar
• Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997; 95: 464–8
   PubMed Web of Science ®Google Scholar
• Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 1987; 48: 94–7
   PubMed Web of Science ®Google Scholar
• Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741–73
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300–7
   PubMed Web of Science ®Google Scholar
• Hay J. Complications at site of injection of depot neuroleptics. Br Med J 1995; 311: 421
   PubMed Web of Science ®Google Scholar
• Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt?. J Clin Psychiatry 2001; 62: 855–9
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double–blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161: 985–95
   PubMed Web of Science ®Google Scholar
• Chue P. Risperidone long-acting injection. Expert Rev. Neurotherapeutics 2003; 3: 435–446
   Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125–32
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–7
   PubMed Web of Science ®Google Scholar
• Eriksson L (2004) , Almqvist A, Mehnert A, Ingham MP, Eriksson B. Treatment with long acting risperidone significantly reduces the need for institutional psychiatric care regardless of previous treatment. In: 45th Annual and 4th Mediterranean Meeting of the Scandinavian College of Neuro-Psychopharmacology (SCNP); 21–24 April, 2004 Juan-les-PinsFrance. Nord J Psychiatry ;58:94–5.
   Google Scholar
• Turner M, Urquhart E. Long term benefits of treatment with risperidone long-acting injection in patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7(Suppl 1)S399
   Google Scholar
• Moeller H, Llorca P, Sacchetti E, Martin S, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121–30
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004; 65: 531–6
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005; 77: 215–27
   PubMed Web of Science ®Google Scholar
• Os JV, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004; 19: 229–32
   PubMedGoogle Scholar
• Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004; 19: 219–25
   PubMed Web of Science ®Google Scholar
• Llorca PM, Bouhours P, Moreau-Mallet V. Improved symptom control, functioning and satisfaction in French patients treated with risperidone long-acting injectable. European Psychiatry 2005.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
   PubMed Web of Science ®Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 1997; 58: 538–46
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. rev. ed. Revised DHEW Pub. No. (ADM). Rockville: Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p 218–20.
   Google Scholar
• Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–63
   PubMed Web of Science ®Google Scholar
• Chouinard G, Ross-Chouinard A, Annable L. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233
   Web of Science ®Google Scholar
• Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004; 19: 241–9
   PubMed Web of Science ®Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.
   Google Scholar
• Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, , et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65, (Suppl 7):4–18; quiz 19–20.
   PubMed Web of Science ®Google Scholar
• Chue P, Cheung R. The impact of weight gain associated with atypical antipsycotic use in schizophrenia. Acta Neuropsychiatr 2004; 16: 1–11
   Google Scholar